Stone Run Capital LLC raised its holdings in shares of AbbVie Inc (NYSE:ABBV) by 19.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,850 shares of the company’s stock after acquiring an additional 800 shares during the quarter. Stone Run Capital LLC’s holdings in AbbVie were worth $447,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also bought and sold shares of the company. Prime Capital Investment Advisors LLC purchased a new position in AbbVie during the 4th quarter valued at about $27,000. Penserra Capital Management LLC purchased a new position in AbbVie during the 4th quarter valued at about $32,000. Larson Financial Group LLC purchased a new position in AbbVie during the 4th quarter valued at about $37,000. Horrell Capital Management Inc. purchased a new position in AbbVie during the 4th quarter valued at about $41,000. Finally, Portfolio Solutions LLC purchased a new stake in shares of AbbVie during the fourth quarter worth about $46,000. Hedge funds and other institutional investors own 69.91% of the company’s stock.
In other news, VP Brian L. Durkin sold 475 shares of the company’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $79.69, for a total transaction of $37,852.75. Following the completion of the transaction, the vice president now owns 9,121 shares in the company, valued at $726,852.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Azita Saleki-Gerhardt sold 15,797 shares of the company’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $79.03, for a total transaction of $1,248,436.91. Following the completion of the sale, the executive vice president now directly owns 93,312 shares of the company’s stock, valued at approximately $7,374,447.36. The disclosure for this sale can be found here. In the last quarter, insiders have sold 41,272 shares of company stock valued at $3,286,290. 0.08% of the stock is owned by insiders.
ABBV stock traded down $0.28 during trading on Thursday, hitting $81.31. 29,458 shares of the company’s stock traded hands, compared to its average volume of 5,525,935. AbbVie Inc has a 52 week low of $75.62 and a 52 week high of $106.32. The firm has a market cap of $119.57 billion, a price-to-earnings ratio of 10.29, a PEG ratio of 1.65 and a beta of 1.14.
AbbVie (NYSE:ABBV) last released its earnings results on Thursday, April 25th. The company reported $2.14 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.08. AbbVie had a net margin of 16.42% and a negative return on equity of 221.09%. The firm had revenue of $7.83 billion during the quarter, compared to analyst estimates of $7.81 billion. During the same quarter in the previous year, the firm earned $1.87 earnings per share. The firm’s revenue for the quarter was down 1.3% compared to the same quarter last year. As a group, equities research analysts predict that AbbVie Inc will post 8.83 earnings per share for the current fiscal year.
A number of equities research analysts recently issued reports on ABBV shares. Argus downgraded shares of AbbVie from a “buy” rating to a “hold” rating in a report on Monday, March 25th. BMO Capital Markets upgraded shares of AbbVie from an “underperform” rating to a “market perform” rating and boosted their target price for the company from $71.00 to $79.00 in a report on Sunday, April 28th. Credit Suisse Group set a $78.00 price target on shares of AbbVie and gave the company a “sell” rating in a research report on Friday, April 26th. UBS Group reaffirmed a “neutral” rating and set a $91.00 price target (down from $97.00) on shares of AbbVie in a research report on Wednesday, January 23rd. Finally, Barclays reissued a “hold” rating and set a $86.00 target price on shares of AbbVie in a research report on Thursday, February 14th. Six analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company’s stock. AbbVie presently has a consensus rating of “Hold” and an average price target of $94.95.
ILLEGAL ACTIVITY WARNING: This news story was reported by Highlight Press and is the sole property of of Highlight Press. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://highlightpress.com/2019/05/23/stone-run-capital-llc-acquires-800-shares-of-abbvie-inc-abbv.html.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Recommended Story: Book Value Per Share in Stock Trading
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.